Loading...

Mologen

XTRA:MGNK
Snowflake Description

Reasonable growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MGNK
XTRA
€35M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
  • Mologen has significant price volatility in the past 3 months.
MGNK Share Price and Events
7 Day Returns
5%
XTRA:MGNK
2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-35.3%
XTRA:MGNK
-11.6%
DE Biotechs
-5.8%
DE Market
MGNK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mologen (MGNK) 5% 10.6% 25.2% -35.3% -79.8% -94%
DE Biotechs 2.7% -1.9% 5.8% -11.6% 95.5% 8.2%
DE Market 1.5% 1.3% 2.2% -5.8% 17.6% 8.7%
1 Year Return vs Industry and Market
  • MGNK underperformed the Biotechs industry which returned -11.6% over the past year.
  • MGNK underperformed the Market in Germany which returned -5.8% over the past year.
Price Volatility
MGNK
Industry
5yr Volatility vs Market

Value

 Is Mologen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Mologen is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Mologen has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mologen. This is due to cash flow or dividend data being unavailable. The share price is €2.93.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mologen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mologen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
XTRA:MGNK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in EUR €-1.52
DB:MGNK Share Price ** DB (2019-06-25) in EUR €2.89
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 22x
Germany Market PE Ratio Median Figure of 425 Publicly-Listed Companies 19.8x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mologen.

XTRA:MGNK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:MGNK Share Price ÷ EPS (both in EUR)

= 2.89 ÷ -1.52

-1.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mologen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Mologen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Mologen's expected growth come at a high price?
Raw Data
XTRA:MGNK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
27%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.02x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mologen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mologen's assets?
Raw Data
XTRA:MGNK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in EUR €-0.10
DB:MGNK Share Price * DB (2019-06-25) in EUR €2.89
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.14x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.8x
XTRA:MGNK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:MGNK Share Price ÷ Book Value per Share (both in EUR)

= 2.89 ÷ -0.10

-28.35x

* Primary Listing of Mologen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mologen has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Mologen's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Mologen's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Mologen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mologen has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Mologen expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mologen expected to grow at an attractive rate?
  • Mologen's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Mologen's earnings growth is expected to exceed the Germany market average.
  • Mologen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
XTRA:MGNK Future Growth Rates Data Sources
Data Point Source Value (per year)
XTRA:MGNK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 27%
XTRA:MGNK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 17.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 45.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 32.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
XTRA:MGNK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
XTRA:MGNK Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 20 1
2022-12-31 3 1
2021-12-31 0 -13 -14 1
2020-12-31 50 38 37 1
2019-12-31 0 -12 -13 2
XTRA:MGNK Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -15
2018-12-31 4 -14 -12
2018-09-30 4 -14 -14
2018-06-30 4 -14 -13
2018-03-31 3 -18 -15
2017-12-31 0 -19 -19
2017-09-30 0 -21 -22
2017-06-30 0 -21 -22
2017-03-31 0 -21 -22
2016-12-31 0 -19 -21
2016-09-30 0 -20 -22
2016-06-30 0 -20 -23

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mologen's earnings are expected to grow significantly at over 20% yearly.
  • Mologen's revenue is expected to grow by 17.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
XTRA:MGNK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Mologen Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:MGNK Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -1.17 -1.17 -1.17 1.00
2020-12-31 3.03 3.03 3.03 1.00
2019-12-31 -1.06 -1.06 -1.06 1.00
XTRA:MGNK Past Financials Data
Date (Data in EUR Millions) EPS *
2019-03-31 -1.52
2018-12-31 -1.52
2018-09-30 -1.90
2018-06-30 -1.89
2018-03-31 -2.06
2017-12-31 -2.82
2017-09-30 -3.21
2017-06-30 -3.60
2017-03-31 -3.91
2016-12-31 -4.25
2016-09-30 -4.74
2016-06-30 -5.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mologen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Mologen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mologen has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Mologen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mologen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mologen does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Mologen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mologen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mologen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mologen Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:MGNK Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1.11 -14.83 5.32 -0.74
2018-12-31 4.08 -11.88 5.27
2018-09-30 3.97 -13.60 5.44
2018-06-30 3.73 -13.32 5.42
2018-03-31 3.03 -14.91 5.46
2017-12-31 0.06 -19.28 5.33
2017-09-30 0.09 -21.60 5.30
2017-06-30 0.11 -21.90 5.18
2017-03-31 0.11 -21.71 5.60
2016-12-31 0.07 -21.00 5.67
2016-09-30 0.03 -21.59 5.78
2016-06-30 0.00 -23.48 5.77
2016-03-31 0.02 -21.87 5.25
2015-12-31 0.04 -20.54 5.28
2015-09-30 0.04 -17.01 5.22
2015-06-30 0.04 -16.10 5.29
2015-03-31 0.02 -16.19 5.20
2014-12-31 0.01 -17.08 5.32
2014-09-30 0.02 -17.36 5.26
2014-06-30 0.06 -14.43 5.10
2014-03-31 0.21 -12.71 5.04
2013-12-31 0.23 -10.83 4.57
2013-09-30 0.19 -9.09 4.32
2013-06-30 0.18 -8.71 4.21
2013-03-31 0.23 -8.37 3.87
2012-12-31 0.32 -7.99 3.70
2012-09-30 0.60 -8.15 3.51
2012-06-30 0.70 -7.86 3.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mologen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Mologen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mologen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mologen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mologen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Mologen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mologen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mologen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mologen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mologen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Mologen has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mologen Company Filings, last reported 2 months ago.

XTRA:MGNK Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31
2018-12-31 -0.95 5.56 8.02
2018-09-30 -7.60 7.01 4.17
2018-06-30 -3.28 5.50 6.21
2018-03-31 0.16 5.46 8.28
2017-12-31 -4.87 5.43 6.52
2017-09-30 -2.19 6.56 9.81
2017-06-30 1.82 6.61 14.15
2017-03-31 6.74 7.09 19.44
2016-12-31 11.84 2.12 20.52
2016-09-30 4.91 0.02 10.19
2016-06-30 9.75 0.02 15.33
2016-03-31 15.04 0.01 20.12
2015-12-31 19.50 0.01 24.59
2015-09-30 26.54 0.02 30.54
2015-06-30 32.79 0.03 34.93
2015-03-31 9.61 0.01 10.71
2014-12-31 13.30 0.01 13.56
2014-09-30 17.05 0.00 17.83
2014-06-30 22.27 0.02 22.88
2014-03-31 25.89 0.00 26.26
2013-12-31 14.98 0.02 14.77
2013-09-30 18.81 0.00 17.56
2013-06-30 21.06 0.01 19.89
2013-03-31 22.87 0.00 21.75
2012-12-31 24.89 0.00 23.78
2012-09-30 26.73 0.00 25.18
2012-06-30 7.84 0.01 6.48
  • Mologen has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Mologen's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mologen has less than a year of cash runway based on current free cash flow.
  • Mologen has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.4% each year.
X
Financial health checks
We assess Mologen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mologen has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Mologen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mologen dividends. Estimated to be 0% next year.
If you bought €2,000 of Mologen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mologen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mologen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
XTRA:MGNK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

XTRA:MGNK Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mologen has not reported any payouts.
  • Unable to verify if Mologen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mologen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mologen has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mologen's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Mologen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mologen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mologen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Mologen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stefan Manth
COMPENSATION €59,000
AGE 62
TENURE AS CEO 0.1 years
CEO Bio

Dr. Stefan M. Manth, M.D., Ph.D., MBA, has been Chief Executive Officer of Genelux Europe and President of Genelux Europe at Genelux Corporation since July 1, 2013. Dr. Manth served as Partner and Change Leader for Strategic Marketing of Chugai Pharmaceutical Co. Ltd. Dr. Manth served as a Senior Vice President and Head of Medical Strategy & Science Unit of Chugai Pharmaceutical Co. Ltd. Dr. Manth served as Medical Officer of Chugai. Dr. Manth has 25 years of experience in the pharmaceutical industry. Dr. Manth served as Chairman of the Board of Mucovax GmbH. Since leaving Roche in 2011, Dr. Manth served as Chairman for Mucovax Scientific and Strategic Advisory Board at Mologen AG. Dr. Manth was Vice Chairman of the Supervisory Board at Mologen AG from August 13, 2014 to April 30, 2019. Dr. Manth served as a Non-Executive Director at Cardiorentis AG. Dr. Manth served as a Member of Scientific Advisory Board at Mologen Holding AG and Mologen AG until September 30, 2012. Dr. Manth received his medical training (MD and internship) at the Freie Universitaet, Berlin and was awarded the title Dr. med. upon completion of a thesis in experimental cardiac surgery. He holds an INSEAD MBA (Fontainebleu, France). He has been Chief Executive Officer and Member of Management board of Mologen AG since May 01, 2019.

CEO Compensation
  • Stefan's compensation has increased whilst company is loss making.
  • Stefan's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Mologen management team in years:

2.1
Average Tenure
  • The tenure for the Mologen management team is about average.
Management Team

Stefan Manth

TITLE
CEO & Member of the Executive Board
COMPENSATION
€59K
AGE
62
TENURE
0.1 yrs

Walter Miller

TITLE
CFO & Member of Executive Board
COMPENSATION
€303K
TENURE
3.2 yrs

Matthias Baumann

TITLE
Chief Medical Officer & Member of Executive Board
COMPENSATION
€346K
AGE
60
TENURE
2.1 yrs

Burghardt Wittig

TITLE
Co-Founder and Chairman of Scientific Advisory Board
COMPENSATION
€645K

Claudia Nickolaus

TITLE
Head of Investor Relations & Corporate Communications
Board of Directors

Oliver Krautscheid

TITLE
Chairman of the Supervisory Board
COMPENSATION
€78K
AGE
50
TENURE
4.8 yrs

Burghardt Wittig

TITLE
Co-Founder and Chairman of Scientific Advisory Board
COMPENSATION
€645K

Ulrich Granzer

TITLE
Member of Scientific Advisory Board
AGE
57

Dirk Arnold

TITLE
Member of Scientific Advisory Board

Viktor Grünwald

TITLE
Member of Scientific Advisory Board

Michael Schultz

TITLE
Member of the Supervisory Board
COMPENSATION
€23K
TENURE
1 yrs

Gerhard Greif

TITLE
Member of the Supervisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Mologen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mologen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases. The company’s lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of colorectal cancer; Phase II trial for the treatment of small lung cancer; and Phase Ib/IIa study of lefitolimod in human immunodeficiency virus-infected patients under antiretroviral therapy through collaborations with the Aarhus University Hospital in Denmark. Its lead product Lefitolimod is also under Phase I combination study with the checkpoint inhibitor Yervoy to treat advanced solid tumors in collaboration with MD Anderson Cancer Center at the University of Texas, the United States. In addition, the company is involved in the development of EnanDIM molecules, which are under pre-clinical development for cancer/anti-infective therapies; and MGN1601, a cell based therapeutic vaccine, which is has completed Phase I/II trial for the treatment of renal cancer. Mologen AG was founded in 1998 and is headquartered in Berlin, Germany.

Details
Name: Mologen AG
MGNK
Exchange: XTRA
Founded: 1998
€35,273,600
12,080,000
Website: http://www.mologen.com
Address: Mologen AG
Fabeckstrasse 30,
Berlin,
Berlin, 14195,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB MGNK Ordinary Shares Deutsche Boerse AG DE EUR 25. Jun 1999
XTRA MGNK Ordinary Shares XETRA Trading Platform DE EUR 25. Jun 1999
BATS-CHIXE MGND Ordinary Shares BATS 'Chi-X Europe' GB EUR 25. Jun 1999
Number of employees
Current staff
Staff numbers
50
Mologen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/25 21:15
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2019/05/28
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.